roxadustat
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Hemodialysis Patients With Renal Anemia
Conditions
Hemodialysis Patients With Renal Anemia
Trial Timeline
May 16, 2016 โ Nov 28, 2017
NCT ID
NCT02779764About roxadustat
roxadustat is a phase 3 stage product being developed by Astellas Pharma for Hemodialysis Patients With Renal Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02779764. Target conditions include Hemodialysis Patients With Renal Anemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05970172 | Phase 3 | Recruiting |
| NCT04408820 | Pre-clinical | Completed |
| NCT04076943 | Phase 2 | Completed |
| NCT03960489 | Phase 1 | Completed |
| NCT02964936 | Phase 3 | Completed |
| NCT02965040 | Phase 1 | Completed |
| NCT02780726 | Phase 3 | Completed |
| NCT02780141 | Phase 3 | Completed |
| NCT02779764 | Phase 3 | Completed |
| NCT01630889 | Phase 2 | Completed |
| NCT01244763 | Phase 2 | Completed |
| NCT01083888 | Phase 1 | Completed |
Competing Products
20 competing products in Hemodialysis Patients With Renal Anemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| ASP7991 | Astellas Pharma | Phase 1 | 33 |
| roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 77 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| ASP1585 | Astellas Pharma | Phase 2 | 52 |
| Kiklin capsules | Astellas Pharma | Pre-clinical | 23 |
| Doravirine | Merck | Approved | 85 |
| BPS804 + Placebo | Novartis | Phase 2 | 52 |
| PA21 + Sevelamer hydrochloride | Kissei Pharmaceutical | Phase 3 | 76 |
| PA21 + PA21 + PA21 + PA21 + Placebo | Kissei Pharmaceutical | Phase 2 | 51 |
| PA21 | Kissei Pharmaceutical | Phase 3 | 76 |
| PA21 | Kissei Pharmaceutical | Phase 3 | 76 |
| [ยนโดC]Etelcalcetide | Amgen | Phase 1 | 32 |
| Epoetin Hospira | Pfizer | Phase 3 | 76 |
| Epoetin Hospira | Pfizer | Phase 3 | 76 |
| sodium thiosulfate | Sanofi | Pre-clinical | 22 |
| Enoxaparine | Sanofi | Approved | 84 |
| Alirocumab 150 MG/ML [Praluent] | Regeneron Pharmaceuticals | Phase 3 | 76 |